Sumitomo Pharmaceutical saw its shares fall 3.7% to ¥1,224 on Tuesday after Gotham City Research published a report accusing the company of materially misstating its fiscal 2025 financials. The short-seller alleges the group overstated profits by as much as ¥165 billion - roughly $1.05 billion - by manipulating trade receivables to make earnings appear stronger.
The Gotham report drew attention to a specific timing anomaly: a ¥48 billion dividend announced by the company’s Swiss subsidiary in March 2026, which was disclosed several weeks before Sumitomo Pharmaceutical released its own financial statements. The short-seller flagged that timing as a discrepancy that raises questions about the integrity of the reported figures. The report also named sister company Sumitomo Chemical in connection with its findings.
Investor unease over the short-seller's claims arrived against an already cautious earnings backdrop for the company. Sumitomo Pharmaceutical’s Q1 FY2027 results, released on July 31, showed operating profit down roughly 10.8% year-over-year. That decline contrasted with a headline net profit increase that management attributed to foreign exchange effects. At the same time, company guidance for the first half of the fiscal year signaled a steep contraction in profitability, leaving investors uncertain about the near-term earnings trajectory prior to the Gotham allegations.
The Tokyo market offered little cushion. The Nikkei 225 came under notable pressure as the Japanese yen surged sharply following confirmation of a joint Japan-U.S. currency market intervention. That development weighed on export-oriented sectors and pulled the broader index lower, amplifying weakness in individual stocks including Sumitomo Pharmaceutical.
Market participants now face overlapping sources of risk: the specific accounting questions raised by Gotham City Research, the legacy of weaker operating performance reported for Q1 FY2027, and broader macro-driven market volatility stemming from sudden currency moves. Each of these threads contributed to the share price move observed on Tuesday.
Clear summary
Short-seller Gotham City Research alleged that Sumitomo Pharmaceutical may have overstated fiscal 2025 earnings by up to ¥165 billion through trade receivables manipulation. The report highlighted a ¥48 billion Swiss-subsidiary dividend announced in March 2026 as a timing discrepancy. The allegations compounded investor concern following a roughly 10.8% decline in operating profit in Q1 FY2027 and first-half guidance pointing to a steep profit contraction. Broader market weakness, intensified by a sharp yen appreciation after confirmed Japan-U.S. intervention, added further downward pressure on the stock.
Key points
- Share movement - Stock fell 3.7% to ¥1,224 following the Gotham City Research report.
- Allegation specifics - The short-seller claims fiscal 2025 figures could be misstated by up to ¥165 billion, citing manipulation of trade receivables and a ¥48 billion dividend timing discrepancy from the Swiss unit.
- Broader context - Q1 FY2027 operating profit was down roughly 10.8% year-over-year and first-half guidance indicated a significant profit contraction; a strengthening yen after confirmed currency intervention pressured the Nikkei 225 and export sectors.
Risks and uncertainties
- Accounting allegations - The short-seller's claims introduce risk around the accuracy of reported fiscal 2025 financials, which could affect investor trust in the company’s reported performance. This primarily affects the pharmaceuticals sector and corporate bond and equity holders of the company.
- Earnings trajectory - Prior weakness in operating profit and guidance for a steep first-half contraction create uncertainty about short-term profitability, impacting investor sentiment in healthcare and related sectors.
- Macro and market volatility - A sharp yen appreciation after confirmed Japan-U.S. currency intervention put pressure on export-oriented sectors and the broader Nikkei 225, increasing market-wide downside risk for Japanese equities.